Breathe Right line extension
This article was originally published in The Tan Sheet
Executive Summary
CNS' new Snore Relief Throat Spray will be marketed with Breathe Right nasal strips as part of $10 mil. TV, cable ad campaign breaking in September. Packages of throat spray will include free samples of nasal strips, instructions to try products together and individually, and coupon for future Breathe Right purchases, CNS says. Snore Relief will begin shipping July 8. Labeling states product is "clinically proven" to reduce snoring and "reduces loudness and frequency of snoring." The spray, which contains a blend of wintergreen, peppermint, menthol, anise and olive oils, as well as a natural astringent, will retail for roughly $10.99...
You may also be interested in...
Sales & Earnings In Brief
McNeil Q2 sales: Second quarter U.S. sales growth of 19% in OTC unit fueled by increased promotional activities for adult Tylenol, pediatric Motrin brands, J&J says during July 16 analysts call. McNeil domestic sales reached $359 mil. in the period, offsetting a 7% decline in international sales to $65 mil. Worldwide revenues for women's health products up 5% to $321 mil. in the quarter, contributing to 7.8% global sales advance to $1.65 bil. for the overall J&J Consumer segment, which includes skin care and baby care products in addition to McNeil and women's health. Also contributing to the gain wereNeutrogena, Clean & Clear skin care products, Viactiv chewable calcium supplements, J&J notes...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.